Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL

The clinical success of ibrutinib validates Bruton tyrosine kinase (BTK) inhibition as an effective strategy for treating hematologic malignancies, including chronic lymphocytic leukemia (CLL). Despite ibrutinib’s ability to produce durable remissions in patients, acquired resistance can develop, mo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood
Autores principales: Reiff, Sean D., Muhowski, Elizabeth M., Guinn, Daphne, Lehman, Amy, Fabian, Catherine A., Cheney, Carolyn, Mantel, Rose, Smith, Lisa, Johnson, Amy J., Young, Wendy B., Johnson, Adam R., Liu, Lichuan, Byrd, John C., Woyach, Jennifer A.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2018
Materias:
Lymphoid Neoplasia
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6128087/
https://ncbi.nlm.nih.gov/pubmed/30018078
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-10-809020
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares